Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.

Abstract

We conducted a prospective multicenter registry of 248 adult patients with immune thrombocytopenia (ITP) treated with rituximab to assess safety. We also assessed response and predictive factors of sustained response. In total, 173 patients received 4 infusions of 375 mg/m(2) and 72 received 2 fixed 1-g infusions 2 weeks apart. The choice of the rituximab… (More)
DOI: 10.1182/blood-2014-06-582346

10 Figures and Tables

Topics

  • Presentations referencing similar topics